Nucleic acid vaccines: prospects for non-viral delivery of mRNA vaccines

@article{Deering2014NucleicAV,
  title={Nucleic acid vaccines: prospects for non-viral delivery of mRNA vaccines},
  author={Raquel Deering and Sushma Kommareddy and Jeffrey B. Ulmer and Luis A. Brito and Andrew J Geall},
  journal={Expert Opinion on Drug Delivery},
  year={2014},
  volume={11},
  pages={885 - 899}
}
Introduction: Nucleic acid-based vaccines are being developed as a means to combine the positive attributes of both live-attenuated and subunit vaccines. Viral vectors and plasmid DNA vaccines have been extensively evaluated in human clinical trials and have been shown to be safe and immunogenic, although none have been licensed for human use. More recently, mRNA-based vaccine alternatives have emerged and might offer certain advantages over their DNA-based counterparts. Areas covered: This… 
Recent innovations in mRNA vaccines.
Development of mRNA vaccines and their prophylactic and therapeutic applications
TLDR
The role of mRNA vaccines are highlighted as prophylactic vaccines for prevention of future infections and as therapeutic vaccines for cancer immunotherapy and RNA replicons (self-amplifying mRNA vaccines) will be described.
Self-amplifying mRNA vaccines.
Nanoparticle-based delivery platforms for mRNA vaccine development
TLDR
Improvements in the NP delivery technologies will contribute to the development of mRNA vaccines with higher efficiency, especially via utilization of NPs in the formulation of vaccine formulations.
Self-replicating alphavirus RNA vaccines
TLDR
This review discusses self-replicating RNA vaccines developed from alphavirus expression vectors, which have been pre-clinically evaluated as vaccines against a number of infectious diseases and cancer.
Vaccines ‘on demand’: science fiction or a future reality
TLDR
This editorial highlights the key milestones in the discovery and development of self-amplifying mRNA vaccines, and reviews how they might be used as a rapid response platform, and points out how future improvements in RNA vector design and non-viral delivery may lead to decreases in effective dose and increases in production capacity.
Lipid-Based Vectors for Therapeutic mRNA-Based Anti-Cancer Vaccines.
TLDR
This review is intended to provide a detailed overview on lipid-based vectors for the development of therapeutic mRNA-based anti-tumor vaccines.
mRNA vaccine: a potential therapeutic strategy
TLDR
The article will discuss the molecular biology of mRNA vaccines and underlying anti-virus and anti-tumor mechanisms, with an introduction of their immunological phenomena, delivery strategies, their importance on Corona Virus Disease 2019 (COVID-19) and related clinical trials against cancer and viral diseases.
Recent advances in mRNA vaccine delivery
TLDR
The necessity of formulating mRNA vaccines with delivery systems with considerable potentials is discussed, and an overview of reported delivery systems is provided.
...
...

References

SHOWING 1-10 OF 124 REFERENCES
Enhanced Delivery and Potency of Self-Amplifying mRNA Vaccines by Electroporation in Situ
TLDR
The utility of EP for the in vivo delivery of large, self-amplifying mRNA, as measured by reporter gene expression and immunogenicity of genes encoding HIV envelope protein is explored.
RNA: the new revolution in nucleic acid vaccines.
DNA vaccines: an historical perspective and view to the future
Summary:  This review provides a detailed look at the attributes and immunologic mechanisms of plasmid DNA vaccines and their utility as laboratory tools as well as potential human vaccines. The
Vaccination with messenger RNA (mRNA).
  • S. Pascolo
  • Biology
    Handbook of experimental pharmacology
  • 2008
TLDR
The structure of mRNA, its possible optimizations for immunization purposes, the different methods of delivery used in preclinical studies, and finally the results of clinical trial where mRNA is the active pharmaceutical ingredient of new innovative vaccines are described.
Developing mRNA-vaccine technologies
TLDR
Based on in situ protein expression, mRNA vaccines are capable of inducing a balanced immune response comprising both cellular and humoral immunity while not subject to MHC haplotype restriction and are an intrinsically safe vector.
A potential disruptive technology in vaccine development: gene-based vaccines and their application to infectious diseases.
  • D. Kaslow
  • Biology
    Transactions of the Royal Society of Tropical Medicine and Hygiene
  • 2004
Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection
TLDR
It is shown that mRNA vaccines induce balanced, long-lived and protective immunity to influenza A virus infections in even very young and very old mice and that the vaccine remains protective upon thermal stress.
Clinical applications of DNA vaccines: current progress.
TLDR
The ability of the current, or second-generation, DNA vaccines to induce more-potent cellular and humoral responses opens up this platform to be examined in both preventative and therapeutic arenas.
mRNA-based gene transfer as a tool for gene and cell therapy.
TLDR
In this work, more insights into the immunological properties of RNA and optimized strategies to produce highly translatable mRNA have increased its efficacy in cellular vaccination and underscore the potential of RNA transfection as a versatile gene therapy tool.
Challenges and advances towards the rational design of mRNA vaccines.
...
...